FDA Approves Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 Vaccine
Pfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read morePfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read morePfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read moreimusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read moreResearchers have made a significant leap forward in the fight against drug-resistant tuberculosis (TB), according to a recent study published in
Read moreAmerican clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read moreIn a groundbreaking development for the vaccine development sector, biotech company Valneva SE announced, that the U.S. Food and Drug
Read moreGSK plc has unveiled entering into a strategic collaboration with Chongqing Zhifei Biological Products, Ltd. (Zhifei), marking a pivotal move
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read more